MyFinsight
Home
About
Contact
amrx: the income statement
Download
Download image
Other Therapeutic
Classes
$9,924K
Hormonal Allergy
$37,685K
Central Nervous System
$77,631K
Other Dosage Forms
$59,662K
Oral Liquid
$16,415K
Biosimilar
$17,009K
Injectable
$54,368K
Transdermal
$47,599K
Ephinephrine Auto Injector
$78,940K
Oral Solid
$180,460K
Product And Service
Other
$8,708K
Institutional
$5,853K
Government Label
$87,755K
Distribution Service
$96,216K
Revenue From Contract
With Customer...
$125,240K
International
$6,288K
Subtotal Dosage Forms
$454,453K
Av KARESegment
$198,532K
Specialty Segment
$125,240K
Affordable Medicines
Segment-US
$460,741K
Net revenue
$784,513K
(11.68%↑ Y/Y)
(benefit from) provision
for income taxes
-$23,355K
(-737.07%↓ Y/Y)
Other operating
income
$117K
Gross profit
$273,974K
(1.64%↑ Y/Y)
Cost of goods sold
$510,539K
(17.93%↑ Y/Y)
Net income (loss)
$18,132K
(54.22%↑ Y/Y)
Income (loss) before
income taxes
-$5,223K
(-133.87%↓ Y/Y)
Operating income (loss)
$70,344K
(-20.79%↓ Y/Y)
Restructuring and other
charges
$143K
(-16.86%↓ Y/Y)
Intellectual property legal
development expenses
$2,437K
(23.89%↑ Y/Y)
Research and development
$63,352K
(3.69%↑ Y/Y)
Selling, general and
administrative
$137,815K
(16.11%↑ Y/Y)
Total other expense,
net
-$75,567K
(-2.97%↓ Y/Y)
Other income, net
$1,235K
(4.84%↑ Y/Y)
Decrease (increase) in
tax receivable...
$20,808K
(283.70%↑ Y/Y)
Loss on refinancing
-$31,365K
Foreign exchange (loss)
gain, net
-$3,431K
(-250.88%↓ Y/Y)
Interest expense, net
-$62,814K
(4.12%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)